Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Blood. 2023 Jun 1;141(22):2780-2783. doi: 10.1182/blood.2022017951.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brentuximab Vedotin
  • Hodgkin Disease* / drug therapy
  • Hodgkin Disease* / pathology
  • Humans
  • Immunoconjugates* / therapeutic use
  • Mediastinal Neoplasms* / drug therapy
  • Nivolumab / therapeutic use

Substances

  • Brentuximab Vedotin
  • Nivolumab
  • Immunoconjugates